Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 219

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer

Open access
Vervoort, Stephin J., Welsh, Sarah A., Devlin, Jennifer R., Barbieri, Elisa, Knight, Deborah A., Offley, Sarah, Bjelosevic, Stefan, Costacurta, Matteo, Todorovski, Izabela, Kearney, Conor J., Sandow, Jarrod J., Fan, Zheng, Blyth, Benjamin, McLeod, Victoria, Vissers, Joseph H.A., Pavic, Karolina, Martin, Ben P., Gregory, Gareth, Demosthenous, Elena, Zethoven, Magnus, Kong, Isabella Y., Hawkins, Edwin D., Hogg, Simon J., Kelly, Madison J., Newbold, Andrea, Simpson, Kaylene J., Kauko, Otto, Harvey, Kieran F., Ohlmeyer, Michael, Westermarck, Jukka, Gray, Nathanael, Gardini, Alessandro, Johnstone, Ricky W.·2021·Cell

Abstract

SUMMARY Gene expression by RNA polymerase II (RNAPII) is tightly controlled by cyclin-dependent kinases (CDKs) at discrete checkpoints during the transcription cycle. The pausing checkpoint following transcription initiation is primarily controlled by CDK9. We discovered that CDK9-mediated, RNAPII-driven transcription is functionally opposed by a protein phosphatase 2A (PP2A) complex that is recruited to transcription sites by the Integrator complex subunit INTS6. PP2A dynamically antagonizes phosphorylation of key CDK9 substrates including DSIF and RNAPII-CTD. Loss of INTS6 results in resistance to tumor cell death mediated by CDK9 inhibition, decreased turnover of CDK9 phospho-substrates, and amplification of acute oncogenic transcriptional responses. Pharmacological PP2A activation synergizes with CDK9 inhibition to kill both leukemic and solid tumor cells, providing therapeutic benefit in vivo. These data demonstrate that fine control of gene expression relies on the balance between kinase and phosphatase activity throughout the transcription cycle, a process dysregulated in cancer that can be exploited therapeutically.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2021.04.022

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 219

Metadata

Authors
Vervoort, S. J., Welsh, S. A., Devlin, J. R., Barbieri, E., Knight, D. A., Offley, S., Bjelosevic, S., Costacurta, M., Todorovski, I., Kearney, C. J., Sandow, J. J., Fan, Z., Blyth, B., McLeod, V., Vissers, J. H. A., Pavic, K., Martin, B. P., Gregory, G., Demosthenous, E., Zethoven, M., Kong, I. Y., Hawkins, E. D., Hogg, S. J., Kelly, M. J., Newbold, A., Simpson, K. J., Kauko, O., Harvey, K. F., Ohlmeyer, M., Westermarck, J., Gray, N., Gardini, A., & Johnstone, R. W.
Venue
Cell
Publisher
Elsevier BV
Published
2021-06
Volume
184
Issue
12
Pages
3143-3162.e32
ISSN
0092-8674 (ISSN-L)
OpenAlex
W3162185013
Cited by
219
References
28
FWCI
10.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. https://app.cochat.ai/papers/10.1016/j.cell.2021.04.022
The paper
Vervoort, S. J., Welsh, S. A., Devlin, J. R., Barbieri, E., Knight, D. A., Offley, S., Bjelosevic, S., Costacurta, M., Todorovski, I., Kearney, C. J., Sandow, J. J., Fan, Z., Blyth, B., McLeod, V., Vissers, J. H. A., Pavic, K., Martin, B. P., Gregory, G., Demosthenous, E., . . . Johnstone, R. W. (2021). The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell. https://doi.org/10.1016/j.cell.2021.04.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.